303. アッシャー症候群 Disease details / Clinical trials / Drug dev / DR info /

臨床試験数 : 10 / 薬物数 : 11 - (DrugBank : 0) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
Blood draw for the laboratory assessment   
   Sanofi
      2013   Phase 1/Phase 2   NCT02065011   France;United States;
Lentiviral vector containing MYO7A gene   
   sanofi-aventis recherche & développement
      2013   Phase 1;Phase 2   EUCTR2012-002574-31-FR   France;United States;
Lentiviral vector containing the human MY07A gene   
   sanofi-aventis recherche & développement
      2013   Phase 1;Phase 2   EUCTR2012-002574-31-FR   France;United States;
NPI-001   
   Nacuity Pharmaceuticals, Inc.
      2020   Phase 1/Phase 2   NCT04355689   Australia;
NT-501   
   Neurotech Pharmaceuticals
      2012   Phase 2   NCT01530659   United States;
QR-421a   
   ProQR Therapeutics
      2021   Phase 2/Phase 3   NCT05176717   United Kingdom;United States;
      2021   Phase 2/Phase 3   NCT05158296   United Kingdom;United States;
      2019   Phase 1/Phase 2   NCT03780257   Belgium;Canada;France;United States;
RNA antisense oligonucleotide for intravitreal injection   
   ProQR Therapeutics
      2021   Phase 2   NCT05085964   Canada;France;United States;
SAR421869   
   Sanofi
      2012   Phase 1/Phase 2   NCT01505062   France;United States;
Sham   
   Neurotech Pharmaceuticals
      2012   Phase 2   NCT01530659   United States;
UshStat (SAR421869)   
   sanofi-aventis recherche & développement
      2013   Phase 1;Phase 2   EUCTR2012-002574-31-FR   France;United States;